

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
22 June 2016 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the May 2016 meeting:

- ***Designated Newly-Approved Drugs***
 - ***Renin-Angiotensin Antihypertensives: sacubitril/valsartan (Entresto)***
 - ***Gastrointestinal-2 (GI-2) Miscellaneous Drugs: eluxadoline (Viberzi)***
- ***Drug Class Reviews***
 - ***Atypical Antipsychotics***
 - ***Anticonvulsant and Anti-Mania Agents***
 - ***Contraceptive Agents—Emergency Contraceptives***
- ***Innovator Drugs***
 - ***Antihemophilic Agents: antihemophilic factor (recombinant) (Kovaltry)***
 - ***Attention Deficit Hyperactivity Disorder (ADHD)—Stimulants: amphetamine ER orally dissolving tablets (Adzenys XR ODT)***
 - ***Narcotic Analgesics and Combinations: buprenorphine buccal film (Belbuca)***
 - ***Psoriasis Agents: calcipotriene/betamethasone dipropionate foam (Enstilar)***
 - ***Antihemophilic Agents: coagulation factor IX (recombinant)/albumin fusion protein (Idelvion)***
 - ***Antiretrovirals Agents: emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey)***

- *Hepatitis C Virus—Direct Acting Antiviral Agents: grazoprevir/elbasvir (Zepatier)*
- *Targeted Immunomodulatory Biologics (TIBs): ixekizumab injection (Taltz)*
- *ADHD—Stimulants: methylphenidate ER chewable tablets (QuilliChew ER)*
- *TIBs: tofacitinib ER tablets (Xeljanz XR)*
- *Binders, Chelators, Antidotes, Overdose Agents: uridine triacetate oral granules (Xuriden)*
- *Utilization Management Issues*
 - *Prior Authorization Criteria*
 - *Oral Oncologic Agents: palbociclib (Ibrance)*
 - *Parkinson’s Disease Agents: carbidopa/levodopa ER capsules (Rytary)*
 - *Gastrointestinal-2 (GI-2) Opioid-Induced Constipation: naloxegol (Movantik)*
 - *Beta-Blockers: nebivolol (Bystolic)*
 - *Non-Steroidal Anti-Inflammatory Agents (NSAIDs): esomeprazole/naproxen (Vimovo) and ibuprofen/famotidine (Duexis)*
 - *Non-Opioid Pain Syndrome Drugs: cyclobenzaprine ER capsules (Amrix)*
 - *Removal of Prior Authorization Criteria*
 - *Topical Pain Drugs: lidocaine 5% patch (Lidoderm)*
 - *“Brand over Generic” Authority and Prior Authorization Criteria*
- *NDAA 2008 Section 703 Actions*
- *Re-evaluation of Nonformulary Agents*
 - *Calcium Channel Blockers*
 - *Proton Pump Inhibitors*

➤ **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.